Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10x Genomics employed 584 workers worldwide at the end of 2019, 852 people at the end of 2020, 1,239 people at the end of 2021 and 1,243 at the end of 2022, the SEC filings showed.

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers. The ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

10x Genomics, Inc. (NASDAQ: TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a ...

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know. 10x Genomics beat analysts’ revenue expectations by 3. ...

Beckman Coulter Life Sciences, and 10x Genomics, Inc. (Nasdaq: TXG), announced a new partnership to expand automation solutions for single cell assay workflows. As part of the agreement, 10x Genomics ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022.

Image Credit: Beckman Coulter Life Sciences. As part of the agreement, 10x Genomics plans to develop dedicated Chromium Single Cell kits to be used on a Biomek i7 Automated Liquid Handler by ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...